[
  {
    "ts": null,
    "headline": "Here's What to Expect From Danaher's Next Earnings Report",
    "summary": "Danaher will release its fourth-quarter earnings later this month, and analysts anticipate bottom-line to remain unchanged year over year.",
    "url": "https://finnhub.io/api/news?id=d965d363e6ad4b565799dca8cbeea5d382ca8e8db12a63338364fb5d5de5c0bb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767784904,
      "headline": "Here's What to Expect From Danaher's Next Earnings Report",
      "id": 138027239,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "DHR",
      "source": "Yahoo",
      "summary": "Danaher will release its fourth-quarter earnings later this month, and analysts anticipate bottom-line to remain unchanged year over year.",
      "url": "https://finnhub.io/api/news?id=d965d363e6ad4b565799dca8cbeea5d382ca8e8db12a63338364fb5d5de5c0bb"
    }
  },
  {
    "ts": null,
    "headline": "Is Danaher (DHR) Pricing In Too Much Optimism After Recent Steady Share Performance",
    "summary": "If you are wondering whether Danaher is reasonably priced or carrying a premium right now, you are in the right place for a closer look at what the current share price might be implying. The stock last closed at US$236.59, with returns of 2.6% over 7 days, 4.6% over 30 days, 2.7% year to date and a 0.4% decline over 1 year. This gives you a mix of recent resilience and relatively flat longer term performance. Recent headlines around Danaher have largely focused on its role in life sciences...",
    "url": "https://finnhub.io/api/news?id=7e071811841e7342af6a02766b76858097f8fd98c6b97ba31f78fa292f11d8d9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767769888,
      "headline": "Is Danaher (DHR) Pricing In Too Much Optimism After Recent Steady Share Performance",
      "id": 138025909,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "DHR",
      "source": "Yahoo",
      "summary": "If you are wondering whether Danaher is reasonably priced or carrying a premium right now, you are in the right place for a closer look at what the current share price might be implying. The stock last closed at US$236.59, with returns of 2.6% over 7 days, 4.6% over 30 days, 2.7% year to date and a 0.4% decline over 1 year. This gives you a mix of recent resilience and relatively flat longer term performance. Recent headlines around Danaher have largely focused on its role in life sciences...",
      "url": "https://finnhub.io/api/news?id=7e071811841e7342af6a02766b76858097f8fd98c6b97ba31f78fa292f11d8d9"
    }
  },
  {
    "ts": null,
    "headline": "Assessing Danaher (DHR) Valuation After Recent Share Price Momentum And Modest Undervaluation Estimate",
    "summary": "With no single headline event driving attention today, Danaher (DHR) is drawing interest as a large healthcare equipment group with US$24.3b in revenue. The company spans biotechnology, life sciences, and diagnostics across multiple global end markets. See our latest analysis for Danaher. Danaher’s recent share price momentum, including a 15.43% 90 day share price return and 4.57% 30 day share price return to US$236.59, contrasts with a slightly negative 1 year total shareholder return. This...",
    "url": "https://finnhub.io/api/news?id=df820b4496dae3bba303eff93b35c42ebf663ad8e4a4ef9b64e318be6642db8c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767759790,
      "headline": "Assessing Danaher (DHR) Valuation After Recent Share Price Momentum And Modest Undervaluation Estimate",
      "id": 138022917,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "DHR",
      "source": "Yahoo",
      "summary": "With no single headline event driving attention today, Danaher (DHR) is drawing interest as a large healthcare equipment group with US$24.3b in revenue. The company spans biotechnology, life sciences, and diagnostics across multiple global end markets. See our latest analysis for Danaher. Danaher’s recent share price momentum, including a 15.43% 90 day share price return and 4.57% 30 day share price return to US$236.59, contrasts with a slightly negative 1 year total shareholder return. This...",
      "url": "https://finnhub.io/api/news?id=df820b4496dae3bba303eff93b35c42ebf663ad8e4a4ef9b64e318be6642db8c"
    }
  }
]